Indian Billionaire Dilip Shanghvi’s Sun Pharma To Buy U.S. Cancer Drug Maker For $355 Million
Sun Pharmaceutical Industries—controlled by Indian billionaire Dilip Shanghvi—has agreed to buy U.S.-based immunotherapy and oncology company Checkpoint Therapeutics for $355 million to bolster the Mumbai-based company’s drug portfolio.
On the heels of FDA nod for cancer drug, Sun Pharma buys Checkpoint Therapeutics for up to $416M
Three months after an FDA approval for cancer immunotherapy Unloxcyt, Checkpoint Therapeutics has found a buyer. | Three months after an FDA approval for cancer immunotherapy Unloxcyt, Checkpoint Therapeutics has found a buyer.
Sun Pharmaceutical Industries Ltd. closed 14.48% below its 52-week high of 1,960.20 rupees, which the company reached on ...
The country's top specialty generics company recently acquired US-based Checkpoint that will further its oncology portfolio ...
Sun Pharma surges 3% on Checkpoint Therapeutics acquisition; Motilal Oswal maintains 'Buy' with 22% upside potential. Read ...
Welcome to the Sun Pharma Stock Liveblog, your real-time source for the latest updates and comprehensive analysis on a ...
Sun Pharma’s acquisition of Checkpoint Therapeutics includes Unloxcyt, an FDA-approved anti-PD-L1 therapy for metastatic and ...
Sun Pharma shares rose like the sun in the intraday trade on Tuesday, as the company shares surged by over 2 per cent in the ...
The stock of the country’s largest pharmaceutical company, Sun Pharmaceutical Industries (Sun Pharma), has declined about 15 ...
Hosted on MSN3d
Sun Pharma Share Price Target Raised to Rs 2,400 – Emkay Research Reiterates ‘BUY’ Rating - DetailsLeading brokerage firm Emkay Research has maintained a bullish stance on Sun Pharma, assigning a ‘BUY’ rating with a price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback